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Abstract: Multimorbidity is the major cause of ill-health and premature death in developed countries.
The ability to identify individuals at risk of developing chronic disease, particularly multimorbidity,
reliably, and simply, and to identify undiagnosed disorders, is vital to reducing the global burden of
disease. This narrative review, the first of recent studies, demonstrates that raised faecal haemoglobin
concentration (f-Hb) is associated with increased all-cause and cause-specific mortality and with
longer-term conditions including diabetes, hypertension, cardiovascular disease, and psoriasis, and
with probable intake of particulate matter. We and others have hypothesized that elevated f-Hb
(measured using a faecal immunochemical test) has considerable potential to identify individuals
at risk of, or who already have, early stage, undiagnosed chronic disease. If f-Hb does prove to be
an effective biomarker for chronic disease and multimorbidity, individuals with detectable f-Hb,
but without an obvious source of gastrointestinal blood loss, could benefit from further assessment
and early intervention. To test this hypothesis rigorously, longitudinal data-linkage methodology
is required linking colorectal cancer screening data, and data on patients presenting with lower
gastrointestinal symptoms, with routinely collected health information.
Keywords: chronic disease; data linkage; faecal haemoglobin; faecal immunochemical test;
inflammation; multimorbidity; screening
1. Introduction
Non-communicable disease is now the major cause of morbidity and premature death
in developed countries, and chronic conditions frequently co-exist [1]. This has led to an
increasing global burden of multimorbidity, defined as two or more chronic conditions
in the same individual [2], particularly in the ageing population [3]. Multimorbidity not
only leads to poorer quality of life [4] and increases the risk of death [5], but it also has
very significant workforce and other resource implications for health care systems [6]. The
ability to identify individuals at risk of developing multimorbidity, reliably and simply,
efficiently, and effectively, and to identify undiagnosed disorders, is vital to reducing the
global burden of disease. This ideal does not exist at present.
As discussed in detail in a recent comprehensive review [7], many developed coun-
tries now have colorectal cancer (CRC) screening programs. High numbers of ostensibly
asymptomatic individuals are now undertaking quantitative faecal immunochemical tests
(FIT) for haemoglobin, which have replaced the now considered obsolete [8], qualitative
guaiac faecal occult blood test (gFOBT) in such programmes; the many advantages of
FIT over gFOBT have been very well documented [7,9,10]. Moreover, quantitative FIT
estimations are now widely used, especially in the UK and Spain [7], in the objective triage
to bowel visualization of patients presenting in primary (and to a lesser extent, secondary)
care with lower bowel symptoms [7,11]. Furthermore, the use of FIT in surveillance pro-
grammes following polypectomy is beginning to be examined in detail, in part due to the
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limited colonoscopy capacity in many countries, but also related to the need for better
clinical care for such patients and the limited benefits of current endoscopic surveillance
programmes [7].
A still unresolved conundrum is why a substantial proportion of those with faecal
haemoglobin concentration (f-Hb) above the thresholds used in screening programmes
and in the assessment of patients with symptoms, have no discernible colorectal pathology
detected on colonoscopy [12]. Such test results are often termed “false positive results”.
While there is considerable evidence of increasing future risk of colorectal neoplasia with
increasing f-Hb [13–17], which holds for those both above and below the threshold for
referral (i.e., f-Hb above the analytical limit of detection [18]), it is still only a small pro-
portion of those with elevated f-Hb who go on to a diagnosis of colorectal neoplasia. This
prompts the question of the source of bleeding in the remaining patients.
However, there is an ever growing literature evaluating the association between f-Hb
and non-communicable diseases unrelated to CRC. This paper aims to briefly review these
contributions, as shown in Table 1, in this first narrative summary on this topic, the studies
having been published in a variety of specialist clinical journals. Moreover, here we also
aim to put forward the unifying hypothesis for all of these findings in which it is proposed
that elevated f-Hb has the potential to identify individuals at risk of, or who have, early
stage undiagnosed chronic disease, and to provide an effective and efficient biomarker
for multimorbidity.
Table 1. Studies demonstrating the association between faecal haemoglobin concentration and diseases other than colorectal






Blood in Faeces 1
Association with Faecal Haemoglobin
Concentration
Chen [19] Taiwan 18,573 FIT Risk for death from CRC 2 and all-cause death.
Libby [20] Scotland 134,192 gFOBT
Increased risk of dying from circulatory disease,
respiratory disease, digestive diseases (excluding CRC),
neuropsychological disease, blood, and endocrine
disease and non-colorectal cancers.
Chien [21] Taiwan 33,355 FIT Risk of cardiovascular diseases.
Moon [22] South Korea 6,277,446 FIT Ischemic stroke, myocardial infarction, andall-cause mortality.
Nakajima [23] Japan 12,836 FIT Glycated haemoglobin.
Kim [24] South Korea 7,946,393 FIT Significantly higher risk of diabetes.
Jung [25] South Korea 5,932,544 FIT
Increased risk of mortality from circulatory disease,
respiratory disease, digestive disease,
neuropsychological disease, blood and endocrine
diseases, and external factors.
Libby [26] Scotland 134,192 gFOBT More likely to have been being prescribed medicines forheart disease, hypertension, diabetes, and depression.
Lee [27] South Korea 1,395,147 FIT Risk of psoriasis.
Ku [28] Taiwan 4,628,995 FIT Ambient fine particulate matter (PM2.5).
1 FIT: faecal immunochemical test; gFOBT: guaiac faecal occult blood test. 2 CRC: colorectal cancer.
2. Elevated f-Hb in Individuals with No Discernable Colorectal Pathology: A Review
2.1. f-Hb and Gastrointestinal Bleeding Caused by Drug Use
Elevated f-Hb in individuals with no pathological findings on colonoscopy is often
attributed to the use of drugs that have the potential to cause gastrointestinal bleeding, but
this remains controversial. A recent systematic review and meta-analysis has documented
that FIT accuracy in CRC screening is not affected by the use of oral anti-coagulants,
aspirin, and non-steroidal anti-inflammatory drugs [29]. In contrast, another recent review
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suggested that aspirin, antiplatelet agents, and oral anti-coagulants significantly lowered
the positive predictive value (PPV) of FIT for detecting advanced colorectal neoplasia
(ACRN) and thus might increase the number of false positive FIT results [30]. Recent
interest has been focused on f-Hb and the use of proton pump inhibitors (PPI) with
the suggestion [31] that PPI could cause false positive FIT results, supporting earlier
work [32,33]: however, this finding has been refuted [34]. The mechanism by which
PPI resulted in an increase in the false positive rate was stated to be unknown, but the
hypothesis presented in [31] was that, consistent with the finding that antibiotic therapy
was also associated with false positive results, it could be inferred that gut dysbiosis
induced by PPI could be the cause. However, the new hypothesis advocated here below
provides an alternative and possibly more attractive explanation. It is considered that
such results could arise because individuals who are taking drugs purportedly causing
elevated f-Hb are, by definition, at high risk of having or developing chronic conditions (see
Section 2.3). There is now good evidence, discussed below, that elevated f-Hb is a marker
of susceptibility to such conditions, probably acting as an index of systemic inflammation,
so that the drugs may not be causing the raised f-Hb, but merely acting as a parallel marker.
2.2. f-Hb and All-Cause Death and Chronic Disease
Observations from a well-established CRC screening programme in Taiwan demon-
strated that, in screened individuals, increasing f-Hb measured by quantitative FIT was
associated with an increasing risk of death not only from CRC, but also from all causes [19].
It was suggested that one biological explanation for this effect might be that an increase in
f-Hb is associated with a decrease in systemic blood haemoglobin concentration, which
had been demonstrated in a previous study to be a strong predictor of all-cause death [35].
Another possible explanation offered was that an increase in f-Hb reflected systemic in-
flammation. The adjusted hazard ratios (HR) increased from 1.43 (95% CI: 1.08–1.88) for
baseline f-Hb of 20–39 ng/mL, to 3.41 (95% CI: 2.02–57·5) for a baseline concentration of
80–99 ng/mL (trend test p < 0·0001), relative to 1–19 ng/mL. Those not referred for further
investigation had the highest risk of incident colorectal neoplasia with adjusted HR 8.46
(95% CI: 6.08–11.76). However, the precise non-CRC causes of death were not investigated,
and corrections for sex, age, and deprivation, all of which are correlated with f-Hb (and
also linked to multimorbidity) [36], were not made.
A study performed in Scotland demonstrated that an abnormal (positive) guaiac
faecal occult blood test (gFOBT) result, which can be considered as a marker for elevated
f-Hb, was shown to be associated with an increased risk of death, not only from CRC,
but also from all-causes, cardiovascular disease, respiratory disease, digestive disease,
neuropsychological conditions, and endocrine disease [20]. After correcting for sex, age,
deprivation, and medicines that might cause gastrointestinal bleeding, these associations
still held. For example, those with a positive test result had a higher risk of dying than
those with a negative result from CRC: HR 7.79 (95% CI: 6.13 to 9.89), p < 0.0001, and
from all non-CRC causes: HR 1.58 (95% CI: 1.45 to 1.73), p < 0·0001. The hypothesis
proposed was that a systemic inflammatory state may be exhibited by subclinical colonic
inflammation, undetected on colonoscopy, but with occult bleeding as a result. The normal
colon is recognised to contain inflammatory cells in the submucosa, reflecting its ongoing
requirement to eliminate organisms that breach the epithelium [37]. It was proposed that
f-Hb might have potential as a modifiable biomarker that could be used to assess the value
of lifestyle and prescribe interventions with the aim of reducing the risk of premature
mortality. In addition, for the different existing patterns of mortality in populations across
the world, f-Hb might also be of value in investigating the reason for these dissimilarities.
The association between high f-Hb and cardiovascular disease has also been demon-
strated in a large community-based FIT screening programme in Taiwan in which 33,355
healthy individuals, free from cardiovascular disease, were followed up. A positive re-
lationship between elevated f-Hb and the development of cardiovascular disease and
subsequent cardiovascular death was reported [21]. The risk of cardiovascular disease
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increased with baseline f-Hb, showing a significant elevated risk of cardiovascular disease
in parallel with the incremental f-Hb with adjusted HR of 1.04, 1.10, 1.40, and 1.23 for
f-Hb of 1–19, 20–49, 50–99 and ≥100 ng/mL, trend test, p < 0.0001, compared with the
reference group with undetectable f-Hb. Additionally highlighted was the need for a better
understanding of the biological mechanisms underlying the relationship between f-Hb and
cardiovascular disease, and the potential use of FIT in a primary prevention strategy was
mentioned. Interestingly, the prediction ability of the model additionally including f-Hb
for the risk of cardiovascular diseases was also higher than that of the model including
traditional atherosclerotic risk factors.
Similarly, researchers in South Korea have highlighted the broader clinical utility
of FIT, based on data from a nationwide population cohort study of over six million
individuals. Results from a multivariable analysis, adjusting for age, sex, smoking, alcohol
consumption, regular exercise, diabetes mellitus, hypertension, dyslipidaemia, and body
mass index found an increased risk of ischemic stroke, myocardial infarction (MI), and
all-cause mortality among those with f-Hb above the threshold used in the screening
programme [22]. The risk of ischemic stroke was higher in the test result positive population
with adjusted HR of 1.09; 95% CI: 1.07–1.11). Similarly, those with positive test results
were at an increased risk of MI (adjusted HR, 1.09; 95% CI: 1.06–1.12). Moreover, increased
all-cause mortality was observed in the positive test result population (adjusted HR, 1.15;
95% CI: 1.07–1.23). It was postulated that estimation of occult blood in faeces may provide
useful information in addition to its conventional role in CRC screening.
Furthermore, a Japanese study has demonstrated an association between FIT posi-
tivity and glycated haemoglobin (HbA1c) concentrations, as used in the diagnosis and
monitoring of diabetes mellitus, in an apparently healthy population undergoing an an-
nual health check. Multivariate logistic regression analysis showed that, compared with
HbA1c of ≤5.69%, HbA1c of ≥6.5% was significantly associated with positive test results.
The association remained when adjusting for demographic and lifestyle factors [23].
This relationship was strongly supported in a recent South Korean study 24]. During
a mean follow-up of 6.5 years, the incidence rates of diabetes were 11.97, 13.60, 14.53,
and 16.82 per 1000 person years in the FIT negative, one-positive, two-positive, and three-
positive groups, respectively. The HR for the incidence of diabetes was 1.14 (95% CI: 1.12 to
1.16; HR, 1.21; 95% CI: 1.16 to 1.27; and HR, 1.40; 95% CI: 1.28 to 1.55) in the one-positive,
two-positive, and three-positive test result groups compared with the negative test result
group, respectively. It was concluded that positive FIT results were associated with a
significantly higher risk of diabetes, suggesting that the FIT can be of value, not only in
CRC screening, but also as a surrogate marker of systemic inflammation.
Recently, a South Korean study aimed to determine whether positive FIT results are
associated with death from various causes in the population [25]. Data were collected
from screening participants who underwent FIT. FIT positive (i.e., f-Hb above the set
threshold) participants had a higher mortality rate than FIT negative (i.e., f-Hb below
the set threshold) participants from CRC. Despite adjusting for age, sex, smoking status,
alcohol consumption habits, body mass index, comorbidity, and aspirin use, FIT positivity
was associated with an increased risk of dying from all non-CRC causes, (adjusted HR, 1.17;
95% CI: 1.15 to 1.18) and CRC (adjusted HR, 5.61; 95% CI: 5.40 to 5.84). Additionally, FIT
positivity was significantly associated with increased mortality from circulatory disease
(adjusted HR, 1.14; 95% CI: 1.11 to 1.17), respiratory disease (adjusted HR, 1.14; 95% CI:
1.09 to 1.19), digestive disease (adjusted HR, 1.57; 95% CI: 1.48 to 1.66), neuropsychological
disease (adjusted HR, 1.08; 95% CI: 1.01 to 1.16), blood and endocrine diseases (adjusted
HR, 1.10; 95% CI: 1.04 to 1.17), and external factors (adjusted HR, 1.16; 95% CI: 1.11 to
1.20). It was concluded that positive FIT results (i.e., elevated f-Hb) are associated with
an increased risk of mortality from CRC and, much more importantly, for various other
chronic diseases, suggesting that it could be a predictor of mortality independent of its
association with CRC.
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2.3. f-Hb and Other Inflammatory States
In Scotland, to further explore the relationship of f-Hb with chronic disease, the
associations between f-Hb and prescription of medicines for a variety of chronic conditions
were investigated [26]. In a cross-sectional approach, data on participants in the gFOBT-
based Scottish Bowel Screening Programme were studied by linking the individuals’ gFOBT
result (classed as abnormal or normal: i.e., elevated or usual f-Hb) with prescribing of
medicines data when the gFOBT was undertaken. Participants with an abnormal gFOBT
result (i.e., an elevated f-Hb) were more likely to have been prescribed medicines for heart
disease, hypertension, diabetes, and depression than those with a normal test result. After
adjustment for sex, age, and deprivation, the associations were maintained with OR 1.35
(95% CI: 1.23 to 1.48), 1.39 (95% CI: 1.27 to 1.52), 1.35 (95% CI:1.15 to 1.58), and 1.36 (95% CI:
1.16 to 1.59), all p < 0.0001 for the four medicine categories, respectively). It was thought
that these results provided additional and substantial weight to the concept that detectable
f-Hb is associated with a range of common chronic conditions that have a component of
systemic inflammation. In addition, it was considered that f-Hb might have potential in
identifying those individuals who are at high risk of developing chronic conditions or who
are at an early stage of disease.
In another recent South Korean study involving screening participants, positive FIT
results were associated with psoriasis, a chronic inflammatory skin disease, suggesting to
the authors a relationship between skin disorders and gut health [27]. The incidence of
psoriasis (per 1000 person-years) was 3.76 versus 4.14 (FIT negative test result versus FIT
positive test result group) during a median follow-up of 6.68 years. In the multivariable-
adjusted model, the HR for psoriasis was 1.03 for one-positive result, 1.12 for two-positive
results, and 1.34 for three-positive FIT results compared with the negative test results.
Moreover, it was documented that epidemiological studies have shown that psoriasis is
associated with dyslipidaemia, obesity, hypertension, diabetes mellitus, and metabolic
syndrome, all of which, as documented above, are associated with elevated f-Hb in the
absence of obvious colorectal pathology. After adjusting for these confounding factors,
positive FIT results were associated with a proportionally increased risk of psoriasis. It
was admitted that the mechanism underlying the association between f-Hb and the risk
of psoriasis was unclear, but it was pointed out that there are several possibilities. A
chronic inflammatory environment may link positive FIT results and psoriasis: FIT can
detect inflammatory conditions manifesting as mucosal ulceration and occult blood loss
as shown in studies on f-Hb and mucosal healing in inflammatory bowel disease [38].
A colonic inflammatory status and the consequent disruption of the intestinal epithelial
barrier (i.e., “leaky gut”) may lead to detectable f-Hb. Indeed, there is evidence that
systemic inflammation can be triggered by a leaky gut [39]. Recently, a range of biomarkers
linking a leaky gut and subsequent bacterial translocation to metabolic health indices
have been identified [40]. Zonulin was the most strongly associated with metabolic health
markers and serum C-reactive protein (CRP), which is applied in routine care as a chronic
inflammation marker. It would be very interesting to explore whether positive relationships
exist between f-Hb and zonulin and other biomarkers in faeces, and perhaps in blood, and
whether these biomarkers could be estimated concomitantly using the specimens collected
for f-Hb estimation in the collection devices used with modern FIT analytical systems, as
has been performed with studies on the faecal microbiome [41].
Finally, an association of ambient fine particulate matter (PM2.5) in the air with
elevated f-Hb has been demonstrated [28]. With data from a large scale FIT based screening
program, and with nationwide exposure data available in Taiwan, the effect of PM.2.5 on
a possible inflammatory response from cells lining the colorectal lining was investigated
by using the proxy indicator of FIT positivity (i.e., elevated f-Hb). Individuals in the high
PM2.5-exposure group showed higher FIT positivity (using 20 µg Hb/g faeces as the
threshold) than those in the low exposure group (9.9% vs. 8.4%). Moreover, it was shown
that there was a positive association between monthly averaged PM2.5 concentrations and
FIT positivity and an increased risk of 11% (95% CI: 10–12). PM2.5 enhanced the risk of
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being in a preclinical state by 14% (95% CI: 10–18) and that of subsequent progression from
a pre-clinical to a clinical state by 21% (95% CI: 14–28).
3. The Hypothesis
The above narrative review amply demonstrates that there is now convincing and ever-
growing evidence to support the hypothesis that elevated f-Hb is associated with increased
all-cause and cause-specific mortality and with long-term conditions including diabetes,
hypertension, cardiovascular disease, psoriasis, and intake of particulate matter. To our
knowledge, there are no works that suggest that f-Hb is not associated with the systemic
inflammation of chronic conditions. The conditions studied to date are all associated with
systemic inflammation, and it is likely that this is reflected in increased, albeit subclinical,
colonic inflammation, which in turn is manifested in occult bleeding detected by FIT. This
may also partly explain the associations seen between f-Hb and the detection of adenoma
at colonoscopy, since adenoma are not necessarily bleeding when viewed endoscopically.
It may be that the inflamed colon is more likely to lead to adenomas, which are detected by
increased f-Hb, rather than bleeding directly from the adenoma. Thus, FIT might be an
effective, simple, inexpensive, and reliable biomarker for systemic inflammation, and hence
for most chronic non-communicable disease. It follows that individuals with detectable
f-Hb, without an obvious source of gastrointestinal bleeding, might benefit from further
assessment and early intervention. Since FIT-based CRC screening is now very widely
undertaken in opportunistic and programmatic approaches, although individuals who
participate in screening tend to be healthier than those who do not, many individuals
without symptoms of disease will have had a detectable f-Hb estimate generated. This
finding might be applied to communicate the risk of future chronic conditions to the
individual as well as to suggest strategies for the minimization of risk. Anecdotally, in the
United Kingdom, it is said that about 10% of consultations in primary care are with patients
presenting with lower gastrointestinal symptoms; FIT is becoming widely used in the triage
of such patients [7] and, as a consequence, a quantitative estimate of f-Hb is also available
for a further large cohort of individuals. We suggest that interventions might be particularly
directed to (1) those who participate in FIT-based screening and have a detectable f-Hb
below the threshold used for referral for bowel visualization; (2) participants in such a
screening who have a f-Hb above the threshold, but who have no detectable colorectal
disease; and (3) those patients who present in primary or secondary care with symptoms,
have a detectable f-Hb, and undergo further investigations, but have no significant bowel
disease detected. Clearly, these suggestions are currently speculative and do require
prospective studies before implementation can be instituted.
4. The Future
Longitudinal data linkage studies are well-suited to determine the extent to which
f-Hb is associated with disease and multimorbidity and, crucially, how f-Hb might be
associated with the onset and progression of chronic disease processes. The first stage in
testing the hypothesis would be to link CRC screening test results (quantitative f-Hb) with
other routinely collected health datasets that provide information on the incidence and
prevalence of chronic disease. For example, in Scotland, f-Hb obtained within the Scottish
Bowel Screening Programme could be linked with routine laboratory data, the Scottish
Morbidity Records of General/Acute Inpatient and Day Case episodes, the Scottish Cancer
Registry, General Register Office (death records), and Prescribing Information Scotland
(to help identify chronic disease that has not resulted in a hospital episode). Similar local
linkage studies could be performed for those patients with symptoms and elevated f-Hb
but no obvious gastrointestinal pathology. Likewise, it might be that if FIT becomes more
widely used in post-polypectomy surveillance, as described recently [42], it is certain that
these patients with detectable f-Hb, but no pathology, would benefit from intervention.
Using advanced statistical approaches, this strategy could be used to determine the f-
Hb threshold that represents a significant risk of chronic disease and multimorbidity. Once
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this has been established, prospective studies would be required to determine the clinical
impact of using FIT to identify individuals who would benefit from early intervention
or preventative measures to treat or arrest the development and progress of the common
components of multimorbidity.
If f-Hb were to prove an effective and efficient biomarker for chronic disease, partic-
ularly multimorbidity, the potential impact would include a fundamental change to our
current health care systems and how individuals currently present with chronic conditions.
FIT could offer significant opportunities to reduce the burden of chronic disease and mul-
timorbidity through initiating prompt interventions to prevent, or minimize, the impact
of these disease processes. These could include drug therapy, weight management and
exercise interventions, dietary (including alcohol) advice, and smoking cessation. Although
there is now ample evidence that FIT appears very promising as an indicator of systemic
inflammation, it must be realized that there are issues that must be considered before wide
adoption of this application of f-Hb [43]. These include the difference between the relative
risk and relative odds, the need to estimate the absolute risk reduction that might be gained
through this application of f-Hb, the importance of carefully assessing the expected and the
accepted false positive rate together with the detection rate, the PPV and its relationship
with the prevalence of the disease, and the need for careful assessment of the benefits and
risks and burdens such as the impact of this application on the provision of additional
health care. Ultimately, after appropriate prospective research, it is possible that the efficacy
of these interventions could be monitored by the objective analyses of serial estimates of
f-Hb using FIT, although little is known at the present time about the utility of this strategy,
particularly in symptomatic patients [44]: the use of serial f-Hb in monitoring responses to
interventions in individuals is, as yet, speculative.
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